IMDC Data Set

The BNM was validated with the latest cut of the IMDC data set containing observational data for patients with metastatic RCC who were receiving nivolumab or everolimus (n = 2,152).¹⁰ Only IMDC centers with nivolumab access and sufficiently reliable data were included. Notably, key exclusion criteria from CM-025 did not apply to patients in IMDC data, and several variables showed moderate-to-high imbalance (see Results on external validation), which makes this a sufficiently distinct cohort for assessing broader model generalizability. However, only 26 (35%) of the baseline variables used for the development of the BNM were available in the IMDC data set, and data on AE were not available in IMDC data. Thus, only OS predictions (at 12 months) were used to validate the BNM to assess real-world generalizability.